Thompson T N, Klaassen C D
Center of Environmental and Occupational Health, Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City 66160-7417, USA.
J Pharm Pharmacol. 1995 Dec;47(12A):1041-7. doi: 10.1111/j.2042-7158.1995.tb03294.x.
The microsomal enzyme inducers 3-methylcholanthrene, phenobarbitone and pregnenolone-16alpha-carbonitrile (PCN) are known to affect other aspects of hepato-biliary disposition in addition to metabolism. This study was designed to determine if presystemic elimination of the non-metabolized xenobiotic ouabain could be altered by these inducers. Male Sprague-Dawley rats were pretreated with inducers or saline for four days. A day later, ouabain (0.5 mg kg-1) was administered into either the ileocolic vein (portal administration) or the femoral vein (systemic administration). Blood and bile samples were collected for up to 90 min after ouabain administration. Biliary excretion rate and cumulative biliary excretion of ouabain were increased by pretreatment with PCN (75 mg kg-1 day-1) relative to controls. Phenobarbitone pretreatment (75 mg kg-1 day-1) also increased these parameters, but to a lesser extent than PCN. In contrast, 3-methylcholanthrene pretreatment (20 mg kg-1 day-1) had no effect on biliary excretion. Plasma concentrations of ouabain were much lower after PCN pretreatment relative to controls, whereas neither phenobarbitone nor 3-methylcholanthrene had any effect. Similarly, clearance (both biliary and total) and volume of distribution were increased by PCN, but not by phenobarbitone or 3-methylcholanthrene pretreatment. Interestingly, the magnitude of biliary and plasma effects induced by PCN appeared to be comparable whether ouabain was administered portally or systemically. Pretreatment of rats with PCN, but not phenobarbitone or 3-methylcholanthrene was shown to increase total clearance of ouabain, mainly via an increase in biliary clearance. Furthermore, because the enhanced clearance occurs after systemic as well as after portal administration of ouabain, a significant change in hepatic presystemic elimination was not detected.
已知微粒体酶诱导剂3-甲基胆蒽、苯巴比妥和孕烯醇酮-16α-腈(PCN)除了影响代谢外,还会影响肝胆处置的其他方面。本研究旨在确定这些诱导剂是否会改变未代谢的外源性哇巴因的首过消除。雄性Sprague-Dawley大鼠用诱导剂或生理盐水预处理4天。一天后,将哇巴因(0.5 mg kg-1)注入回结肠静脉(门静脉给药)或股静脉(全身给药)。在给予哇巴因后长达90分钟内收集血液和胆汁样本。与对照组相比,用PCN(75 mg kg-1天-1)预处理可增加哇巴因的胆汁排泄率和累积胆汁排泄量。苯巴比妥预处理(75 mg kg-1天-1)也增加了这些参数,但程度低于PCN。相比之下,3-甲基胆蒽预处理(20 mg kg-1天-1)对胆汁排泄没有影响。与对照组相比,PCN预处理后哇巴因的血浆浓度要低得多,而苯巴比妥和3-甲基胆蒽均无任何影响。同样,PCN可增加清除率(胆汁清除率和总清除率)和分布容积,而苯巴比妥或3-甲基胆蒽预处理则无此作用。有趣的是,无论哇巴因是经门静脉给药还是全身给药,PCN诱导的胆汁和血浆效应的程度似乎相当。结果表明,用PCN而非苯巴比妥或3-甲基胆蒽预处理大鼠可增加哇巴因的总清除率,主要是通过增加胆汁清除率。此外,由于在哇巴因全身给药和门静脉给药后均出现清除率增强,因此未检测到肝首过消除的显著变化。